Corcept Therapeutics is a pharmaceutical company which discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome. The Company is also developing Korlym in different combinations to treat patients with triple-negative breast cancer and metastatic castration-resistant prostate cancer. In addition, it develops product candidates for the treatment of Cushing's syndrome and solid-tumor cancers.

Type
Public
HQ
Menlo Park, US
Founded
1998
Size (employees)
103 (est)
Corcept Therapeutics was founded in 1998 and is headquartered in Menlo Park, US
Report incorrect company information

Corcept Therapeutics Office Locations

Corcept Therapeutics has an office in Menlo Park
Menlo Park, US (HQ)
149 Commonwealth Drive
Show all (1)
Report incorrect company information

Corcept Therapeutics Financials and Metrics

Corcept Therapeutics Financials

Corcept Therapeutics's revenue was reported to be $81.32 m in FY, 2016 which is a 61.7% increase from the previous period.
USD

Net income (Q1, 2018)

17.5 m

EBIT (Q1, 2018)

21 m

Market capitalization (21-May-2018)

2.1 b

Closing share price (21-May-2018)

18.2

Cash (31-Mar-2018)

33.1 m
Corcept Therapeutics's current market capitalization is $2.1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

10.4 m26.6 m50.3 m81.3 m

Revenue growth, %

156%89%62%

Cost of goods sold

143 k882 k1.4 m2.1 m3.6 m

Gross profit

10.2 m25.7 m48.9 m79.3 m
Quarterly
USDQ2, 2017Q3, 2017Q1, 2018

Cost of goods sold

775 m976 m1.2 m

General and administrative expense

14.1 b16.5 b18.4 m

R&D expense

7.9 b11.7 b17.1 m

Operating expense total

22.8 b29.1 b36.7 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

54.9 m24.2 m40.4 m51.5 m31.1 m

Accounts Receivable

Inventories

910 k1.4 m642 k2.3 m4.6 m

Current Assets

58.3 m30.2 m49 m65.7 m124.2 m
Quarterly
USDQ2, 2017Q3, 2017Q1, 2018

Cash

33.6 m31.1 m33.1 m

Inventories

3.1 m3.8 m4.9 m

Current Assets

81.3 m93.9 m150.8 m

PP&E

499 k553 k577 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(46 m)(31.4 m)(6.4 m)8.1 m129.1 m

Inventories

(290 k)(531 k)799 k(682 k)(2.3 m)

Accounts Payable

(1.4 m)(495 k)(561 k)965 k6.3 m

Cash From Operating Activities

(37.1 m)(27.4 m)3.1 m18.4 m60.9 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

17.5 m

Inventories

1 m1.1 m1.1 m1.1 m1.3 m1.5 m1.6 m1.9 m2.1 m2.3 m2.9 m590 k

Accounts Payable

2.3 m3.7 m2.6 m2 m1 m2.4 m1.7 m2.1 m2.1 m4.3 m4.3 m(759 k)

Cash From Operating Activities

34.4 m
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information